Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Rhea-AI Summary
Palatin Technologies (NYSE American: PTN) has announced it will release its first quarter fiscal year 2025 financial results on November 14, 2024, before U.S. markets open. The company will host a conference call and webcast at 11:00 a.m. ET the same day, featuring executive management's review of operating results and development program updates. The earnings release is scheduled for 7:30 a.m. ET, with a conference call replay available until November 28, 2024. Palatin is a biopharmaceutical company focused on developing first-in-class medicines based on melanocortin receptor systems.
Positive
- None.
Negative
- None.
News Market Reaction – PTN
In the trading session that priced this news, PTN gained 12.07%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast | |
Q1 Fiscal Year 2025 Results Press Release | 11/14/2024 at 7:30 a.m. ET |
Q1 Fiscal Year 2025 Conference Call-Live | 11/14/2024 at 11:00 a.m. ET |
US Toll Free Dial-In Number: | 1-888-506-0062 |
International Dial-In Number: | 1-973-528-0011 |
Participant Access Code: | 176159 |
Q1 Fiscal Year 2025 Conference Call-Replay | 11/14/2024-11/28/2024 |
US Toll Free Dial-In Number: | 1-877-481-4010 |
International Dial-In Number: | 1-919-882-2331 |
Participant Access Code: | 51641 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-first-quarter-fiscal-year-2025-results-teleconference-and-webcast-to-be-held-on-november-14-2024-302300035.html
SOURCE Palatin Technologies, Inc.